ClinicalTrials.gg
RecruitingNCT05143619Updated Oct 6, 2026

Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines

An observational study in Hepatocellular Carcinoma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center — 6 open to participants now, 15 under way, none of them phase 3. Carcinoma, Hepatocellular · M.D. Anderson Cancer Center.

Started
2019
with 2 others
Observational
2 of 36
1 open now
Primary completion
2027-02
later than 5 of 14 live
Registered
32nd of 36
by date

Among the 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center, this one is one of 3 that started in 2019, is one of 2 observational ones, reaches primary completion later than 5 of the 14 other live ones, and was the 32nd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

6 of the 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "Teaching the Teachers" involves teaching the guidelines to experts who later teach the same guidelines to other radiologists, trainees, and physicians to assume the teacher's role and disseminate the guidelines and so on.

Read the detailed description

PRIMARY OBJECTIVES:

I. Evaluate the magnitude of teaching of hepatocellular carcinoma (HCC) diagnostic guidelines after applying "Teaching the Teachers" concept.

II. Assess the effect of "Teaching the Teachers" concept on application of guidelines in clinical practice.

OUTLINE:

Participants complete surveys immediately after completion of a HCC diagnostic guideline webinar, monthly thereafter, and again at 6 months.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Abdominal radiologists with expertise in liver imaging working in academic, community, and governmental practices in many centers around the world.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physicians who finished radiology residency
  • Radiologists with current or completed specialized training in abdominal imaging
  • Radiologists with expertise in liver imaging with no minimum number of years of experience
  • Radiologists working in academic, community, and governmental practices
  • Radiologists with current practice in any country around the globe
  • Radiologists with and without previous knowledge of HCC diagnosis guidelines (Liver Imaging Reporting and Data System [LI-RADS])
  • Radiologists with interest in education and/or teaching

Exclusion criteria

Exclusion Criteria:

  • Physicians with no formal training in radiology
  • Radiologists with no expertise in abdominal/liver imaging
  • Current radiology residents
  • Radiologists with no interest in education and/or teaching
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)

Groups and cohorts

  • Observational (surveys)

    Participants complete surveys immediately after completion of a HCC diagnostic guideline webinar, monthly thereafter, and again at 6 months.

    Other: Survey Administration

Interventions

  • OtherSurvey Administration

    Complete surveys

06

What researchers measure

Primary outcomes

  1. Teaching rates of the hepatocellular carcinoma diagnosis guidelines

    Paired comparisons will be performed on the proportion of learners using the practice guidelines. Will perform a multivariate analysis to assess the effect of demographic characteristics (e.g., number of years of experience, type of practice) on the teaching rate of the HCC diagnostic guidelines.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Feb 2027, 92 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 92 months is above that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2021
First posted
Dec 3, 2021
StartActual
May 10, 2019
Primary completionEst.
Feb 2, 2027
CompletionEst.
Feb 2, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05143619
Responsible party
Sponsor
First posted
Dec 3, 2021
Start date
May 10, 2019
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Khaled M Elsayes, MD
Contact
kmelsayes@mdanderson.org
(713) 794-1191
Khaled M Elsayes, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion